Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) IBS Treatment Market Research Report 2019-2025

Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global IBS Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 IBS-D
      • 1.3.3 IBS-C
      • 1.3.4 IBS-M
    • 1.4 Market Segment by Application
      • 1.4.1 Global IBS Treatment Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Research Laboratories
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global IBS Treatment Market Size
      • 2.1.1 Global IBS Treatment Revenue 2014-2025
      • 2.1.2 Global IBS Treatment Sales 2014-2025
    • 2.2 IBS Treatment Growth Rate by Regions
      • 2.2.1 Global IBS Treatment Sales by Regions 2014-2019
      • 2.2.2 Global IBS Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 IBS Treatment Sales by Manufacturers
      • 3.1.1 IBS Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 IBS Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 IBS Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 IBS Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 IBS Treatment Price by Manufacturers
    • 3.4 Key Manufacturers IBS Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into IBS Treatment Market
    • 3.6 Key Manufacturers IBS Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 IBS-D Sales and Revenue (2014-2019)
      • 4.1.2 IBS-C Sales and Revenue (2014-2019)
      • 4.1.3 IBS-M Sales and Revenue (2014-2019)
    • 4.2 Global IBS Treatment Sales Market Share by Type
    • 4.3 Global IBS Treatment Revenue Market Share by Type
    • 4.4 IBS Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global IBS Treatment Sales by Application

    6 United States

    • 6.1 United States IBS Treatment Breakdown Data by Company
    • 6.2 United States IBS Treatment Breakdown Data by Type
    • 6.3 United States IBS Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union IBS Treatment Breakdown Data by Company
    • 7.2 European Union IBS Treatment Breakdown Data by Type
    • 7.3 European Union IBS Treatment Breakdown Data by Application

    8 China

    • 8.1 China IBS Treatment Breakdown Data by Company
    • 8.2 China IBS Treatment Breakdown Data by Type
    • 8.3 China IBS Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World IBS Treatment Breakdown Data by Company
    • 9.2 Rest of World IBS Treatment Breakdown Data by Type
    • 9.3 Rest of World IBS Treatment Breakdown Data by Application
    • 9.4 Rest of World IBS Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World IBS Treatment Sales by Countries
      • 9.4.2 Rest of World IBS Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Allergan Plc (Ireland)
      • 10.1.1 Allergan Plc (Ireland) Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.1.4 IBS Treatment Product Introduction
      • 10.1.5 Allergan Plc (Ireland) Recent Development
    • 10.2 Sucampo Pharmaceuticals (U.S.)
      • 10.2.1 Sucampo Pharmaceuticals (U.S.) Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.2.4 IBS Treatment Product Introduction
      • 10.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
    • 10.3 Ironwood Pharmaceuticals, Inc. (U.S.)
      • 10.3.1 Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.3.4 IBS Treatment Product Introduction
      • 10.3.5 Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
    • 10.4 Astellas Pharma Inc. (Japan)
      • 10.4.1 Astellas Pharma Inc. (Japan) Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.4.4 IBS Treatment Product Introduction
      • 10.4.5 Astellas Pharma Inc. (Japan) Recent Development
    • 10.5 Valeant Pharmaceuticals (Canada)
      • 10.5.1 Valeant Pharmaceuticals (Canada) Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.5.4 IBS Treatment Product Introduction
      • 10.5.5 Valeant Pharmaceuticals (Canada) Recent Development
    • 10.6 Abbott Laboratories (U.S.)
      • 10.6.1 Abbott Laboratories (U.S.) Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.6.4 IBS Treatment Product Introduction
      • 10.6.5 Abbott Laboratories (U.S.) Recent Development
    • 10.7 Synergy Pharmaceuticals, Inc. (U.S.)
      • 10.7.1 Synergy Pharmaceuticals, Inc. (U.S.) Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.7.4 IBS Treatment Product Introduction
      • 10.7.5 Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
    • 10.8 Ardelyx, Inc. (U.S.)
      • 10.8.1 Ardelyx, Inc. (U.S.) Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.8.4 IBS Treatment Product Introduction
      • 10.8.5 Ardelyx, Inc. (U.S.) Recent Development
    • 10.9 Nestle (Switzerland)
      • 10.9.1 Nestle (Switzerland) Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.9.4 IBS Treatment Product Introduction
      • 10.9.5 Nestle (Switzerland) Recent Development
    • 10.10 Sebela Pharmaceuticals (Ireland)
      • 10.10.1 Sebela Pharmaceuticals (Ireland) Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of IBS Treatment
      • 10.10.4 IBS Treatment Product Introduction
      • 10.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
    • 10.11 Probi (Sweden)
    • 10.12 Alfasigma USA, Inc. (Italy)
    • 10.13 RedHill Biopharma Ltd. (Israel)
    • 10.14 AstraZeneca (U.K)
    • 10.15 Ipsen (France)
    • 10.16 Novartis AG (Switzerland)
    • 10.17 Takeda Pharmaceutical Company Ltd (Japan)
    • 10.18 Synthetic Biologics, Inc. (U.S.)
    • 10.19 Protagonist Therapeutics Inc. (U.S.)
    • 10.20 Pfizer Inc (U.S.)
    • 10.21 Lexicon Pharmaceuticals, Inc. (U.S.)
    • 10.22 Innovate Biopharmaceuticals (U.S.)

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 IBS Treatment Sales Channels
      • 11.2.2 IBS Treatment Distributors
    • 11.3 IBS Treatment Customers

    12 Market Forecast

    • 12.1 Global IBS Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global IBS Treatment Sales Forecast by Type
    • 12.3 Global IBS Treatment Sales Forecast by Application
    • 12.4 IBS Treatment Forecast by Regions
      • 12.4.1 Global IBS Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global IBS Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
      Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
      In 2019, the market size of IBS Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for IBS Treatment.

      This report studies the global market size of IBS Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the IBS Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Allergan Plc (Ireland)
      Sucampo Pharmaceuticals (U.S.)
      Ironwood Pharmaceuticals, Inc. (U.S.)
      Astellas Pharma Inc. (Japan)
      Valeant Pharmaceuticals (Canada)
      Abbott Laboratories (U.S.)
      Synergy Pharmaceuticals, Inc. (U.S.)
      Ardelyx, Inc. (U.S.)
      Nestle (Switzerland)
      Sebela Pharmaceuticals (Ireland)
      Probi (Sweden)
      Alfasigma USA, Inc. (Italy)
      RedHill Biopharma Ltd. (Israel)
      AstraZeneca (U.K)
      Ipsen (France)
      Novartis AG (Switzerland)
      Takeda Pharmaceutical Company Ltd (Japan)
      Synthetic Biologics, Inc. (U.S.)
      Protagonist Therapeutics Inc. (U.S.)
      Pfizer Inc (U.S.)
      Lexicon Pharmaceuticals, Inc. (U.S.)
      Innovate Biopharmaceuticals (U.S.)

      Market Segment by Product Type
      IBS-D
      IBS-C
      IBS-M

      Market Segment by Application
      Hospitals
      Clinics
      Research Laboratories

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the IBS Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key IBS Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of IBS Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now